A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction

Trial Profile

A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Adenocarcinoma; Breast cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 14 Apr 2017 Planned initiation date changed from 1 Jul 2016 to 1 Jun 2016.
    • 09 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top